---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-008873"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-26T00:04:51.538376+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025

## Summary
- Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.
- Cash, equivalents, and investments $204.5M at Dec 31, 2024, up from $135.2M.
- Initial clinical data from PM359 Phase 1/2 for p47 phox CGD expected in 2025.
- IND/CTA filing for PM577 (Wilson's Disease) planned for first half of 2026.
- Cash runway expected into first half of 2026.

## SEC filing metadata
- accession: 0001628280-25-008873
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025008873/0001628280-25-008873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025008873/prme-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-008873
- JSON: https://secwatch.observer/filing/0001628280-25-008873.json
- Plain text: https://secwatch.observer/filing/0001628280-25-008873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.